The Bioretec’s RemeOs Spinal Interbody Cage implant. Credit: Bioretec.

The US Food and Drug Administration (FDA) has awarded breakthrough device designation for Bioretec’s RemeOs Spinal Interbody Cage implant, marking a significant advancement in spinal surgery technology.

The designation is pivotal for the company’s strategy to introduce the product to the US market.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Bioretec’s RemeOs implant is designed to restore intervertebral height and enable intervertebral body fusion in the cervical spine.

The company is now assessing the impact of this advancement on its product development timelines and capital requirements.

Bioretec CEO Timo Lehtonen said: “This designation gives us another validation of our expertise in creating innovative products for the unmet clinical needs in the orthopaedic field. I am enthusiastic about the future prospects and the market opportunities of this product, which is based on the patented hybrid technology.”

See Also:

The FDA’s recognition confirms that the RemeOs Spinal Cage could potentially reduce hospital stays, enhance patient quality of life, and deliver long-term clinical benefits.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The Breakthrough Devices Program will facilitate priority discussions between Bioretec and the FDA to discuss the implant’s commercial availability in the US.

In 2022, Bioretec submitted an application seeking a CE mark for its bioresorbable RemeOs trauma screw to commercialise in the European Union (EU).

The magnesium alloy trauma screw is part of the company’s new RemeOs product family.

Bioretec’s new RemeOs product line is based on a magnesium alloy and hybrid composite. It offers a new generation of strong biodegradable materials for enhanced surgical outcomes.

The RemeOs implants are absorbed and replaced by bone to eliminate the need for surgery and enable fracture healing.